Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL
Fig 3
T cell and clonotype expansion after allogeneic stem cell transplantation and adoptive transfer of EBV-specific T cells.
(A) Flow cytometric monitoring of absolute numbers of CD4+ and CD8+ T cells and EBV DNA copy number in peripheral blood. Relapse of the CD4+ T cell lymphoma was detected on day 56 in peripheral blood. Time points of Rituximab application are marked with an asterisk (*). ATCT = adoptive T cell transfer. (B) TCR clonotype diversity in CD4+ and CD8+ T cells in peripheral blood of the patient. For comparison, the diversity in donor’s PBMC is shown. (C) Flow cytometric monitoring of peripheral blood CD8+ T cells using HLA peptide-MHC multimers (EPL, RAK, HPV) on the day of ATCT (day 105) and thereafter. (D) Cumulative frequency of TCR clonotypes specific for each of the epitopes EPL, RAK, and HPV in CD8+ T cell populations. Data points for donor’s PBMC, T cell product after peptide stimulation, and peripheral blood of the patient before (day 60) and after ATCT (day 120, day 180, and day 230) are shown.